Innoviva Total Liabilities 2010-2024 | INVA

Innoviva total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Innoviva Annual Total Liabilities
(Millions of US $)
2023 $569
2022 $666
2021 $400
2020 $392
2019 $383
2018 $389
2017 $610
2016 $732
2015 $752
2014 $745
2013 $382
2012 $214
2011 $346
2010 $354
2009 $370
Innoviva Quarterly Total Liabilities
(Millions of US $)
2024-09-30 $563
2024-06-30 $559
2024-03-31 $564
2023-12-31 $569
2023-09-30 $561
2023-06-30 $563
2023-03-31 $568
2022-12-31 $666
2022-09-30 $686
2022-06-30 $572
2022-03-31 $555
2021-12-31 $400
2021-09-30 $395
2021-06-30 $395
2021-03-31 $392
2020-12-31 $392
2020-09-30 $387
2020-06-30 $387
2020-03-31 $382
2019-12-31 $383
2019-09-30 $392
2019-06-30 $396
2019-03-31 $390
2018-12-31 $389
2018-09-30 $386
2018-06-30 $494
2018-03-31 $489
2017-12-31 $610
2017-09-30 $614
2017-06-30 $669
2017-03-31 $726
2016-12-31 $732
2016-09-30 $738
2016-06-30 $741
2016-03-31 $750
2015-12-31 $752
2015-09-30 $761
2015-06-30 $756
2015-03-31 $749
2014-12-31 $745
2014-09-30 $747
2014-06-30 $793
2014-03-31 $342
2013-12-31 $382
2013-09-30 $336
2013-06-30 $509
2013-03-31 $500
2012-12-31 $214
2012-09-30 $211
2012-06-30 $210
2012-03-31 $212
2011-12-31 $346
2011-09-30 $342
2011-06-30 $341
2011-03-31 $343
2010-12-31 $354
2010-09-30 $354
2010-06-30 $358
2010-03-31 $363
2009-12-31 $370
2009-09-30 $359
2009-06-30 $366
2009-03-31 $359
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.195B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03